Cogent Biosciences, Inc. has entered into a material Commercial Supply Agreement with Hovione FarmaCiencia S.A. to secure the manufacturing and supply of its drug, bezuclastinib. The agreement, effective September 1, 2026, covers the production of bezuclastinib in both spray-dried dispersion and tablet forms.
Key Details
- Agreement: A Commercial Supply Agreement with Hovione FarmaCiencia S.A. to manufacture and supply bezuclastinib.
- Term: The agreement has an initial term of five years, followed by automatic successive two-year renewal periods.
- Purchase Commitment: Cogent will purchase the product based on rolling forecasts and is committed to buying specified minimum percentages of its requirements from Hovione, with these percentages decreasing over the agreement's term.